

# Pasquale Pignatelli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3480266/pasquale-pignatelli-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

294  
papers

8,486  
citations

51  
h-index

77  
g-index

319  
ext. papers

10,034  
ext. citations

6.4  
avg, IF

6.19  
L-index

#	Paper	IF	Citations
294	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry.. <i>Platelets</i> , <b>2022</b> , 1-6	3.6	
293	Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	0
292	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis.. <i>Antioxidants</i> , <b>2022</b> , 11,	7.1	2
291	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. <i>Lancet, The</i> , <b>2022</b> , 399, 1383-1390	40	9
290	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study.. <i>Journal of Autoimmunity</i> , <b>2022</b> , 129, 102832	15.5	
289	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk: A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 785	3.6	
288	Extra Virgin Olive Oil Reduces Gut Permeability and Metabolic Endotoxemia in Diabetic Patients. <i>Nutrients</i> , <b>2022</b> , 14, 2153	6.7	3
287	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.. <i>Thrombosis Journal</i> , <b>2021</b> , 19, 102	5.6	0
286	Toll-like receptor 4 activation in platelets from myocardial infarction patients. <i>Thrombosis Research</i> , <b>2021</b> , 209, 33-40	8.2	1
285	Interventional study with vitamin E in cardiovascular disease and meta-analysis. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 178, 26-41	7.8	5
284	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 779503	5.4	2
283	Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicentre observational study. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	7
282	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , <b>2021</b> , 209, 69-74	8.2	3
281	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 345, 7-13	3.2	13
280	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , <b>2021</b> , 23, E184-E188	1.5	3
279	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 102-105	7	16
278	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2063-2068	3.7	2

277	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , <b>2021</b> , 26,	4.8	4
276	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , <b>2021</b> , 165, 105418	10.2	7
275	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients <b>2021</b> , 10,		1
274	Beneficial effects of a combination of natural product activators of autophagy on endothelial cells and platelets. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 2146-2159	8.6	4
273	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 168, 1-5	7.8	0
272	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 66, 28-36	8.5	4
271	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102821	13.6	3
270	Low-Grade Endotoxemia and Thrombosis in COVID-19. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00348	4.2	5
269	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 695961	5.6	1
268	Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. <i>Platelets</i> , <b>2021</b> , 32, 1009-1017	3.6	3
267	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
266	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
265	Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	1
264	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1231-1237	3.7	6
263	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 379-387	3.7	13
262	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100410	17.1	5
261	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , <b>2021</b> , 322, 245-249	3.3	3
260	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13771	2.9	3

259	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , <b>2021</b> , 141, 1-6	3	2
258	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 658-665	6.4	10
257	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 327, 176-182	3.2	5
256	Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13397	4.6	8
255	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f11-f19	6.4	10
254	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14064	2.9	1
253	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1583-1591	3.7	5
252	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 80-85	3.9	6
251	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
250	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 715878	5.4	5
249	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 2904-2911	4.5	6
248	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , <b>2021</b> , 22, 434-444	2.7	2
247	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2455-2463	3.8	14
246	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , <b>2020</b> , 126, 1415-1442	15.7	14
245	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1". <i>Circulation Research</i> , <b>2020</b> , 126, e114-e115	15.7	1
244	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 755-758	3.7	12
243	Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis. <i>Hemodialysis International</i> , <b>2020</b> , 24, 383-396	1.7	1
242	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5

241	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 80, 73-77	3.9	3
240	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , <b>2020</b> , 127, 400-401	15.7	43
239	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , <b>2020</b> , 105, 562-572	6.6	43
238	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3424-3430	7.5	6
237	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1034-1040	6	16
236	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 588-593	4.5	6
235	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 949-956	7	129
234	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , <b>2020</b> , 152, 355-362	7.8	8
233	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 355-360	5.1	8
232	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 513-520	6.4	5
231	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , <b>2020</b> , 71, 235-241	2.1	2
230	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620945792	2.3	5
229	Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008477	6.4	0
228	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?. <i>Drugs</i> , <b>2020</b> , 80, 1383-1396	12.1	57
227	Nox2 activation in Covid-19. <i>Redox Biology</i> , <b>2020</b> , 36, 101655	11.3	65
226	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1291-1298	5.3	8
225	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13378	4.6	74
224	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 135-143	3.7	9

223	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	11
222	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1662-1668	3	15
221	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 723-728	3	7
220	Alirocumab after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2074-2075	59.2	1
219	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 561-576	4.3	10
218	Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking (SUR - VAPES) 2 Randomized Trial. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e010455	6	65
217	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 519-525	13.6	22
216	The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 107	5.7	4
215	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , <b>2019</b> , 6, 17	5.4	4
214	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , <b>2019</b> , 163, 111-118	6	11
213	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , <b>2019</b> , 70, 257-263	2.1	10
212	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219676	3.7	7
211	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , <b>2019</b> , 289, 195-200	3.1	8
210	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 31, 786-790	8.4	3
209	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2436	15.1	
208	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012596	6	13
207	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2019</b> , 6, 001180	1.2	0
206	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 508-515	3.8	14

205	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1261-1267	6.4	57
204	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 856-861	2.4	39
203	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 37-43	6.4	8
202	Silybin and metabolic disorders. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 1-3	3.7	1
201	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 21-38	3.7	8
200	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 54, 34-39	3.9	14
199	Reply: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient?. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 706-707	15.1	
198	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2018</b> , 255, 69-73	3.2	17
197	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , <b>2018</b> , 274, 29-34	3.1	9
196	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 651-660	3.7	9
195	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2018</b> , 200, 32-36	4.9	11
194	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , <b>2018</b> , 69, 795-802	2.1	25
193	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , <b>2018</b> , 17, 830-836	1.2	5
192	Aging and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. <i>Journal of Nutrition, Health and Aging</i> , <b>2018</b> , 22, 73-81	5.2	10
191	Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 183-190	3.7	5
190	Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1477-1481	3	47
189	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , <b>2018</b> , 82, 1286-1292	2.9	3
188	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , <b>2018</b> , 76, 713-722	0.9	83

187	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <i>Open Heart</i> , <b>2018</b> , 5, e000837		3
186	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009509	6	6
185	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , <b>2018</b> , 264, 58-63	3.2	50
184	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 936-943	3	10
183	Carotid plaque detection improves the predictive value of CHADS-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 231, 143-149	3.3	16
182	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 387-406	3.7	40
181	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , <b>2017</b> , 7, 3797	4.9	7
180	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	60
179	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 41, 33-38	3.9	27
178	Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality". <i>Atherosclerosis</i> , <b>2017</b> , 256, 148-149	3.1	
177	NADPH Oxidase-2 and Atherothrombosis: Insight From Chronic Granulomatous Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2017</b> , 37, 218-225	9.4	55
176	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , <b>2017</b> , 27, 1083-1124	8.4	66
175	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1455-1462	15.1	39
174	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1558-1570	7	36
173	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186961	3.7	15
172	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 619-624	3.2	11
171	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , <b>2016</b> , 25, 751-755	8.4	9
170	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 36, 74-80	3.9	11



169	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	34
168	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , <b>2016</b> , 73, 107-14	18.9	32
167	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2895	1.8	33
166	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , <b>2016</b> , 8, 275-83	2.1	26
165	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 199-204	3.7	30
164	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 934-5	3.2	
163	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , <b>2016</b> , 244, 48-50	3.1	13
162	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , <b>2016</b> , 7, 39143-39147	3.3	10
161	NOX 5 is expressed in platelets from patients with chronic granulomatous disease. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 198-200	7	6
160	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 856-63	7	26
159	Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F in HIV-1 patients on abacavir-based therapies. <i>HIV Medicine</i> , <b>2016</b> , 17, 774-777	2.7	
158	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 814-816	3.2	
157	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	102
156	Enhanced Soluble Serum CD40L and Serum P-Selectin Levels in Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , <b>2016</b> , 48, 440-5	3.1	9
155	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , <b>2016</b> , 113, 484-489	10.2	18
154	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, e31-3	3.9	2
153	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. <i>Nutrition and Diabetes</i> , <b>2015</b> , 5, e172	4.7	57
152	Response to "Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality". <i>International Journal of Cardiology</i> , <b>2015</b> , 189, 247-8	3.2	

151	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , <b>2015</b> , 23, 682-7	8.4	41
150	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2015</b> , 120, 50-5	3.7	29
149	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , <b>2015</b> , 6, e113	4.2	17
148	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta: Refers to Sevket Balta, MD et al. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 225-6	3.2	
147	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 513-6	3.2	50
146	Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review. <i>Antioxidants and Redox Signaling</i> , <b>2015</b> , 23, 514-32	8.4	23
145	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , <b>2015</b> , 34, 899-903	5.9	22
144	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2015</b> , 180, 1-5	3.2	30
143	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , <b>2015</b> , 179, 139-43	3.2	18
142	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 876-82	7	12
141	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 617-24	7	38
140	Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. <i>Chest</i> , <b>2015</b> , 147, 1644-1650	5.3	53
139	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , <b>2015</b> , 70, 651-8	18.9	17
138	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , <b>2015</b> , 5, e008026	3	17
137	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 647-51	3	88
136	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , <b>2015</b> , 17, 1223-8	3.9	12
135	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2015</b> , 170, 490-7.e1	4.9	22
134	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , <b>2015</b> , 70, 961-6	7.3	33

133	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 5945-50	3.3	4
132	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 123-31	3.7	30
131	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. <i>Europace</i> , <b>2014</b> , 16, 1107-16	3.9	35
130	Statins as regulators of redox signaling in platelets. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 1300-12	8.4	12
129	Platelet activation is associated with myocardial infarction in patients with pneumonia. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1917-25	15.1	105
128	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. <i>Atherosclerosis</i> , <b>2014</b> , 235, 649-58	3.1	51
127	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 81	3	52
126	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. <i>Trends in Cardiovascular Medicine</i> , <b>2014</b> , 24, 142-8	6.9	22
125	Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia?. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 2949-54	8.4	22
124	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 566-70	3.9	17
123	LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. <i>Atherosclerosis</i> , <b>2014</b> , 237, 108-16	3.1	67
122	New insights into the steen solution properties: breakthrough in antioxidant effects via NOX2 downregulation. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2014</b> , 2014, 242180	6.7	17
121	Epicatechin and catechin modulate endothelial activation induced by platelets of patients with peripheral artery disease. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2014</b> , 2014, 691015	6.7	24
120	Platelet NOX, a novel target for anti-thrombotic treatment. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 817-23		51
119	Total adiponectin is inversely associated with platelet activation and CHADSEVASC score in anticoagulated patients with atrial fibrillation. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 908901	4.3	13
118	Does enhancement of oxidative stress markers mediate health effects of ambient air particles?. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 21, 46-51	8.4	12
117	Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3,	6	47
116	Oxidative stress in patients affected by primary aldosteronism. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 2022-9; discussion 2029	1.9	40

115	Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous disease. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000920	6	28
114	Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 577-84	6	12
113	Role of platelets in NOX2 activation mediated by TNF $\alpha$ in heart failure. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 179-85	3.7	15
112	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 632-8	3.3	9
111	Reply: ankle-brachial index in patients with nonvalvular atrial fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1457-8	15.1	1
110	Mechanisms And Management Of Thrombo-Embolic In Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2014</b> , 7, 1112	0.8	14
109	Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2255-6	15.1	44
108	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1053-8	15.4	32
107	Does NADPH oxidase deficiency cause artery dilatation in humans?. <i>Antioxidants and Redox Signaling</i> , <b>2013</b> , 18, 1491-6	8.4	25
106	Statins as antithrombotic drugs. <i>Circulation</i> , <b>2013</b> , 127, 251-7	16.7	117
105	NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. <i>International Journal of Cardiology</i> , <b>2013</b> , 165, 184-92	3.2	45
104	Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 406-12	9.4	46
103	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. <i>Atherosclerosis</i> , <b>2013</b> , 231, 392-400	3.1	36
102	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3241-7	3.2	9
101	Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property". <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 81-2	3.3	1
100	Letter by Violi et al regarding article, "molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition". <i>Circulation: Cardiovascular Imaging</i> , <b>2013</b> , 6, e3	3.9	
99	Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2013</b> , 2, 379-88	4.3	14
98	Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000364	6	27

97	Relationship between platelet and urinary 8-Iso-PGF <sub>2</sub> levels in subjects with different degrees of NOX2 regulation. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000198	6	20
96	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 1032-8	4.6	28
95	Early increase of NOX2-derived oxidative stress in children: relationship with age. <i>Pediatric Research</i> , <b>2013</b> , 73, 788-93	3.2	9
94	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 384-7	7.1	23
93	Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. <i>Journal of Pediatrics</i> , <b>2012</b> , 161, 1004-9	3.6	60
92	Platelet oxidative stress and thrombosis. <i>Thrombosis Research</i> , <b>2012</b> , 129, 378-81	8.2	75
91	"Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply". <i>Liver International</i> , <b>2012</b> ,	7.9	
90	Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply. <i>Liver International</i> , <b>2012</b> , 32, 1028-1028	7.9	
89	Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. <i>Biochemical Pharmacology</i> , <b>2012</b> , 84, 1635-42	6	31
88	Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. <i>Circulation</i> , <b>2012</b> , 126, 92-103	16.7	115
87	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 219-27	3.7	36
86	Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 125-32	15.4	59
85	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , <b>2012</b> , 98, 1063-6	5.1	24
84	Platelet isoprostane overproduction in diabetic patients treated with aspirin. <i>Diabetes</i> , <b>2012</b> , 61, 1626-32.	32.9	41
83	Serum levels of vitamin E are associated with early recurrence of atrial fibrillation after electric cardioversion. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2012</b> , 5, 327-33	6.4	13
82	Moderate weight loss decreases oxidative stress and increases antioxidant status in patients with metabolic syndrome. <i>ISRN Obesity</i> , <b>2012</b> , 2012, 960427		10
81	Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. <i>Cardiovascular Therapeutics</i> , <b>2011</b> , 29, 385-94	3.3	17
80	Megakaryocyte TLR2: immunity bullet?. <i>Blood</i> , <b>2011</b> , 117, 5791-2	2.2	0

79	Effect of L-carnitine on oxidative stress and platelet activation after major surgery. <i>Acta Anaesthesiologica Scandinavica</i> , <b>2011</b> , 55, 1022-8	1.9	20
78	NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. <i>Liver International</i> , <b>2011</b> , 31, 1533-40	7.9	33
77	Effects of resveratrol and other wine polyphenols on vascular function: an update. <i>Journal of Nutritional Biochemistry</i> , <b>2011</b> , 22, 201-11	6.3	129
76	Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 1766-71	9.4	31
75	NOX2-mediated arterial dysfunction in smokers: acute effect of dark chocolate. <i>Heart</i> , <b>2011</b> , 97, 1776-81	5.1	51
74	Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 423-34	9.4	114
73	Nutrition, supplements, and vitamins in platelet function and bleeding. <i>Circulation</i> , <b>2010</b> , 121, 1033-44	16.7	59
72	Letter by Violi et al regarding article, "Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization". <i>Circulation</i> , <b>2010</b> , 122, e429; author reply e430	16.7	
71	Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 360-7	9.4	91
70	Nutraceuticals in the early infancy. <i>Cardiovascular Therapeutics</i> , <b>2010</b> , 28, 236-45	3.3	2
69	Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , <b>2010</b> , 213, 225-34	3.1	44
68	Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 221-9	5	51
67	Role of NADPH oxidase in atherosclerosis. <i>Future Cardiology</i> , <b>2009</b> , 5, 83-92	1.3	56
66	Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. <i>Circulation</i> , <b>2009</b> , 120, 1616-22	16.7	113
65	Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 444-51	6.1	12
64	Myeloperoxidase overexpression in children with hypercholesterolemia. <i>Atherosclerosis</i> , <b>2009</b> , 205, 239-43	3.1	15
63	Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1832-4	15.4	12
62	Statins enhance circulating vitamin E. <i>International Journal of Cardiology</i> , <b>2008</b> , 123, 172-4	3.2	10

61	Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. <i>Pediatrics</i> , <b>2008</b> , 122, e648-55	7.4	53
60	Letter by Violi and Pignatelli regarding article, "Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study". <i>Circulation</i> , <b>2008</b> , 117, e312; author reply e313	16.7	2
59	Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure. <i>Cardiovascular Research</i> , <b>2008</b> , 78, 515-22	9.9	24
58	C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 752-7	9.4	25
57	Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. <i>British Journal of Nutrition</i> , <b>2008</b> , 100, 1276-82	3.6	60
56	Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. <i>Journal of Nutrition</i> , <b>2008</b> , 138, 1602-8	4.1	108
55	Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. <i>European Heart Journal</i> , <b>2008</b> , 29, 54-62	9.5	47
54	Early increase of oxidative stress and soluble CD40L in children with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1974-81	15.1	30
53	Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 1170-8	15.4	51
52	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. <i>Free Radical Biology and Medicine</i> , <b>2007</b> , 43, 853-9	7.8	56
51	Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. <i>European Heart Journal</i> , <b>2007</b> , 28, 608-12	9.5	89
50	LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes. <i>FASEB Journal</i> , <b>2007</b> , 21, 927-34	0.9	47
49	Endothelial dysfunction and peripheral arterial disease: reply. <i>European Heart Journal</i> , <b>2007</b> , 28, 1910-1913	9.5	3
48	Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 2763-8	9.4	65
47	Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. <i>Diabetologia</i> , <b>2006</b> , 49, 1169-74	10.3	37
46	Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. <i>FASEB Journal</i> , <b>2006</b> , 20, 1082-9	0.9	103
45	Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, e131-2	9.4	27
44	Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 2577-8	9.4	43

43	Aspirin resistance. <i>Lancet, The</i> , <b>2006</b> , 367, 606-17	40	433
42	Aspirin resistance. <i>Lancet, The</i> , <b>2006</b> , 367, 2059-60	40	4
41	Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. <i>Atherosclerosis</i> , <b>2006</b> , 188, 77-83	3.1	157
40	Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. <i>Journal of Vascular Surgery</i> , <b>2006</b> , 44, 525-30	3.5	49
39	Aspirin resistance: is this term meaningful?. <i>Current Opinion in Hematology</i> , <b>2006</b> , 13, 331-6	3.3	9
38	The need for a consistent definition of "aspirin resistance". <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 1618-9	15.4	5
37	CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 35-42	15.1	52
36	Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. <i>Blood</i> , <b>2005</b> , 106, 1992-4	2.2	75
35	Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 2784-9	15.4	60
34	Vitamin C inhibits platelet expression of CD40 ligand. <i>Free Radical Biology and Medicine</i> , <b>2005</b> , 38, 1662-67.8		32
33	Early anticoagulant effect of atorvastatin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2005</b> , 25, e145; author reply e145-6	9.4	
32	Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. <i>Circulation</i> , <b>2005</b> , 111, 412-9	16.7	139
31	The polyphenols quercetin and catechin synergize in inhibiting platelet CD40L expression. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 888-9	7	12
30	gp91phox-dependent expression of platelet CD40 ligand. <i>Circulation</i> , <b>2004</b> , 110, 1326-9	16.7	126
29	Aspirin. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 338-9	15.4	4
28	Aspirin. The antiplatelet effect of aspirin. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 335-6	15.4	6
27	Vitamin E for the treatment of cardiovascular disease: is there a future?. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1031, 292-304	6.5	24
26	Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 1693-4		14



25	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 979-84	15.1	113
24	Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. <i>Journal of Hypertension</i> , <b>2004</b> , 22, 1151-6	1.9	32
23	Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O <sub>2</sub> - production. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 317-25	7	53
22	Metformin decreases platelet superoxide anion production in diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2002</b> , 18, 156-9	7.5	44
21	Red and white wine differently affect collagen-induced platelet aggregation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2002</b> , 32, 356-8		22
20	Increased Superoxide Anion Production by Platelets in Hypercholesterolemic Patients. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 796-801	7	41
19	Involvement of GD3 in platelet activation. A novel association with Fc gamma receptor. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2002</b> , 1583, 297-304	5	15
18	Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. <i>Haematologica</i> , <b>2002</b> , 87, 420-6	6.6	18
17	Increased superoxide anion production by platelets in hypercholesterolemic patients. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 796-801	7	5
16	Involvement of the glycoprotein Ib-V-IX complex in nickel-induced platelet activation. <i>Environmental Health Perspectives</i> , <b>2001</b> , 109, 225-8	8.4	4
15	The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. <i>American Journal of Clinical Nutrition</i> , <b>2000</b> , 72, 1150-5	7	215
14	Superoxide Anion and Hydroxyl Radical Release by Collagen-induced Platelet Aggregation - Role of Arachidonic Acid Metabolism. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 83, 485-490	7	86
13	Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 2542-7	9.4	38
12	Concomitant activation of G <sub>i</sub> protein-coupled receptor and protein kinase C or phospholipase C is required for platelet aggregation. <i>FEBS Letters</i> , <b>1999</b> , 460, 37-40	3.8	16
11	Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. <i>Journal of the American Geriatrics Society</i> , <b>1999</b> , 47, 943-7	5.6	20
10	Concomitant activation of G <sub>i</sub> and G <sub>q</sub> protein-coupled receptors does not require an increase in cytosolic calcium for platelet aggregation. <i>FEBS Letters</i> , <b>1998</b> , 435, 115-8	3.8	14
9	Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients. <i>Platelets</i> , <b>1998</b> , 9, 309-14	3.6	4
8	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. <i>Blood</i> , <b>1998</b> , 91, 484-490	2.2	251

7	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. <i>Blood</i> , <b>1998</b> , 91, 484-490	2.2	7
6	Nickel Enhances Collagen-induced Platelet Activation Acting by Increasing the Organization of the Cytoskeleton. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 79, 395-399	7	5
5	Mechanism of the persisting TxA2 receptor antagonism by picotamide. <i>Thrombosis Research</i> , <b>1997</b> , 85, 207-15	8.2	9
4	Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. <i>Circulation</i> , <b>1997</b> , 95, 885-91	16.7	103
3	Effects of storage on in vitro platelet responses: comparison of ACD and Na citrate anticoagulated samples. <i>Journal of Clinical Laboratory Analysis</i> , <b>1996</b> , 10, 134-9	3	10
2	Acid citrate dextrose (ACD) formula A as a new anticoagulant in the measurement of in vitro platelet aggregation. <i>Journal of Clinical Laboratory Analysis</i> , <b>1995</b> , 9, 138-40	3	18
1	Effect of picotamide on the calcium mobilization and phospholipase C activation in human platelets. <i>Thrombosis Research</i> , <b>1994</b> , 74, 453-61	8.2	7